Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...
Gain Therapeutics (GANX) provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback